The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.
Also called NCT01062763
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 119 participants
- Sponsor
- Ib Abildgaard Jacobsen
- Registry
-
NCT01062763 -
2009-017033-22
-
- Other papers using this trial's data
- Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01062763. Randomized; quadruple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-05-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
- Acronym
- SDHDS
- Condition
- Arterial Hypertension
- Condition
- Hypertension, Resistant to Conventional Therapy
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- spironolactone
- Intervention (Drug)
- placebo
- Lead sponsor
- Ib Abildgaard Jacobsen
Record details
- Record id
cardio:ct-nct01062763- Content hash
6def9bfe575837325e2d5325b7c539c28095811c62242af12df173240380f832